RemeGen: Subsidiary receives drug clinical trial approval notice for Adebly monoclonal antibody injection and SHR-8068 injection

Hengrui Pharmaceuticals announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd., have received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approval of Atezolizumab Injection and SHR-8068 Injection. Clinical trials will be conducted soon. Atezolizumab Injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company, and SHR-8068 Injection is a fully humanized anti-CTLA-4 monoclonal antibody introduced by the company. According to the requirements of China's drug registration laws and regulations, after obtaining the Drug Clinical Trial Approval Notice, clinical trials must still be conducted and approved by the National Medical Products Administration before production and listing.